Zevra Therapeutics (ZVRA) Operating Margin (2019 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Operating Margin came in at 143.97% in Q1 2026, up 17025.0% YoY from N/an in Q1 2025, and up 428.12% on a QoQ basis from 27.26% in Q4 2025.
Zevra Therapeutics (ZVRA) Operating Margin (2019 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 8 years of Operating Margin data on file, last reported at 143.97% in Q1 2026.
- Quarterly Operating Margin rose 17025.0% year-over-year to 143.97% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4.44% (up 17301.0% YoY) and the FY2025 annual result came in at 59.12%, up 30935.0% from the prior year.
- Operating Margin advanced to 143.97% in Q1 2026, from 27.26% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 143.97% in Q1 2026 to a low of 1978.19% in Q2 2022.
- A 5-year average of 370.34% and a median of 257.67% in 2022 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2022 — Operating Margin slumped 202686 bps — and 2023, when it surged 190438 bps.
- Tracing ZVRA's Operating Margin over 5 years: stood at 460.58% in 2022, then soared by 75 bps to 117.31% in 2023, then declined by 9 bps to 128.34% in 2024, then soared by 121 bps to 27.26% in 2025, then soared by 428 bps to 143.97% in 2026.
- The last three Operating Margin figures came in at 143.97% (Q1 2026), 27.26% (Q4 2025), and 15.9% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | 42.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.26% |
| Mar 31, 2026 | 143.97% |
| Dec 31, 2025 | 27.26% |
| Sep 30, 2025 | 15.90% |
| Jun 30, 2025 | -274.48% |
| Mar 31, 2025 | -26.28% |
| Dec 31, 2024 | -128.34% |
| Sep 30, 2024 | -739.00% |
| Jun 30, 2024 | -540.80% |
| Mar 31, 2024 | -598.13% |
| Dec 31, 2023 | -117.31% |
| Sep 30, 2023 | -530.71% |
| Jun 30, 2023 | -73.81% |
| Mar 31, 2023 | -404.00% |
| Dec 31, 2022 | -460.58% |
| Sep 30, 2022 | -240.86% |
| Jun 30, 2022 | -1,978.19% |
| Dec 31, 2021 | -110.07% |
| Sep 30, 2021 | -113.08% |
| Jun 30, 2021 | 48.67% |